A systematic review reveals that African children of 15-17 years demonstrate low hepatitis B vaccine seroprotection rates.

ABSTRACT: Childhood HBV immunization remains globally fundamental to the elimination of hepatitis B virus (HBV). However, monitoring proportions of HBV vaccine seroprotection and their determinants among African Pediatric recipients is crucial. This study sought to verify extent of immune protection accorded by the HBV vaccine in African children of up to 17 years of age by pooling the prevalence of seroprotection reported by primary studies conducted in the Northern, Western, and Southern African regions. We included 19 eligible articles out of the 197 initially downloaded, published from 1999 to 2021 from African Journals Online (AJOL), EMBASE, Scopus, and PubMed. The study protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO), University of York Cent

SUBMITTER: Muwanda F 

PROVIDER: S-EPMC10719251 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature